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The reaction of aldimines with α-(hydroxyimino)ketones of type 10 (1,2-diketone 
monooximes) was used to prepare 2-unsubstituted imidazole 3-oxides 11 bearing a 
functionalized alkyl residue at N(1). These products were transformed into the 
corresponding imidazole-2-ones 13 and imidazole-2-thiones 14 by treatment with Ac2O 
and 2,2,4,4-tetramethylcyclobutane-1,3-dithione, respectively. The three-component 
reaction of 10, formaldehyde, and an alkane-1,ω-diamine 15 gave the bis-(imidazole 3-
oxides) 16. With Ac2O, 2,2,4,4-tetramethylcyclobutane-1,3-dithione or Raney-Ni, the 
latter reacted to give the corresponding bis-(imidazol-2(3H)-ones) 19, bis-(imidazol-
2(3H)-thiones) 20, and bis-imidazoles 22, respectively. The structures of 11a and 16b 
were established by X-ray crystallography. 
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1. Introduction. – 
The importance of imidazole and benzimidazole derivatives both in the field of 
biologically active compounds and in organic synthesis is well documented (see for 
example [1–9]). Complexes of imidazoles [10] and imidazole derived carbenes [11] 
with diverse metal cations have also been studied extensively. In a series of recent 
papers, the synthesis of 2-unsubstituted imidazole N-oxides was reported [12–15]. 
These derivatives were shown to be useful starting materials for the preparation of other 
imidazoles, such as imidazole-2-thiones, imidazole-2-carbonitriles, imidazol-2-ones, 
and N-alkyl or N-arylimidazol-2-amines. An important feature of the structure of 
imidazole N-oxides 1 is their similarity with nitrones, which are well known 1,3-dipoles 
applied for the synthesis of N,O-containing five-membered heterocycles [16]. In the 
case of the electron-deficient 2,2-bis(trifluoromethyl)ethene-1,1-dicarbonitrile (BTF, 2), 
the reaction with 2-unsubstituted imidazole-3-oxides 1 led to imidazol-2-
ylidenepropanedinitriles 3 and hexafluoroacetone. The formation of these products 
occurred via a regioselective [2+3]-cycloaddition to give 4 and subsequent 
fragmentation to produce 3 (Scheme 1). The reaction was proposed to proceed stepwise 
via a zwitterionic intermediate 5, which, in the presence of H2O, underwent the 
conversion to imidazol-2-ones [15]. 
 
Scheme 1 
 
A similar reaction pattern is observed when perfluoropropene is used as a dipolarophile. 
After elimination of carbonic difluoride (F2C=O), the labile cycloadduct of type 4 gives 
the corresponding 2-(1,2,2,2-tetrafluoroethyl)imidazole [17]. 
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Recently, new approaches for the synthesis of both imidazoles and imidazole N-
oxides were published [18] [19]. Taking into account that imidazole N-oxides can easily 
be deoxygenated, the second approach opens access to a larger number of differently 
functionalized derivatives. Considering the type of starting materials applied in the 
syntheses of imidazole N-oxides, oximes and mono-oximes of 1,2-dicarbonyl 
compounds (α-(hydroxyimino)ketones) are of special interest. In the latter case, the 
synthesis can be performed with an aldimine or, alternatively, in a three-component 
reaction with a primary amine and an aldehyde. However, it has been reported that in 
the three-component reaction with formaldehyde, isomerization of the initially formed 
imidazole N-oxide to the corresponding imidazol-2-one already takes place in the 
reaction mixture [20].  
As a continuation of our studies on imidazoles and imidazole N-oxides, the 
preparation of imidazole N-oxides bearing functionalized side chains should be 
elaborated. The only report on optically active imidazole N-oxides presented a method 
based on the use of α-amino acids as the amino component in the three-component 
reaction [21]. However, racemization during the formation of the imidazole ring was a 
serious problem, and in some cases, only completely racemized products were obtained. 
In a very recent paper, chiral β-aminoalcohols with the stereogenic centre in the α- or β-
position were reacted with glyoxal, formaldehyde, and ammonia to give optically active 
imidazoles of type 6 and 7 [9]. In another paper, the same method is reported for the 
synthesis of bis-imidazole 8. The authors claim that by using (R,R)-and (S,S)-1,2-
diphenylethane-1,2-diamine the (R,R) and (S,S) enantiomer of 8, respectively, was 
obtained. However, no data regarding their optical activity or e,e-values are given [18]. 
 
Formulae 6, 7, and 8 
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To the best of our knowledge, there are no known reports on the preparation of 
imidazoles and bis-(imidazole N-oxides) by using aminoalcohols and diamines, 
respectively, in reactions with α-(hydroxyimino)ketones. In the present paper, we 
describe first results of this approach. 
 
2. Results and Discussion. – 
2.1. Preparation of 1-(Hydroxyalkyl)imidazole 3-Oxides. In analogy to the already 
described preparations of 1,3,5-tris-(2-hydroxyethyl)- and 1,3,5-tris-(3-hydroxypropyl)-
perhydro-1,3,5-triazines (12a and 12b, resp.) [22], compounds 12c, 12d and 12e were 
obtained by treatment of the corresponding aminoalcohols with paraformaldehyde in 
MeOH. The crude products were used for the condensation with α-
(hydroxyimino)ketones 10 in refluxing EtOH (Scheme 2). Under these conditions, 
perhydrotriazines 12 are known to undergo dissociation [12], and the monomeric 
formaldehyde imines reacted with 10 to give imidazole 3-oxides 11 (Table 1) according 
to the known mechanism (cf. [23]). 
 
Scheme 2 
 
Table 1. Imidazole 3-Oxides 11 Prepared from 10 and 12. 
 
All imidazole 3-oxides 11 were characterized by their spectroscopic and 
analytical data. In most cases, the crystalline products contained variable amounts of 
H2O. The 1H-NMR spectra show a characteristic down-field shifted signal for H–C(2) at 
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8.2–8.5 ppm. Furthermore, the structure of 11a was established by X-ray 
crystallography (Fig.1).  
 
Fig. 1. ORTEP-Plot [24] of the molecular structure of 11a (arbitrary numbering of the 
atoms, 50% probability ellipsoids, the H2O molecule is not shown) 
 
The asymmetric unit contains one zwitterionic molecule and half of a H2O 
molecule, which sits on a C2-axis. The hydroxy group forms an intermolecular H-bond 
with the oxide O-atom of a neighboring molecule and thereby links the molecules into 
extended chains which run in the [1 –1 0] and  [1 1 0] directions and can be described 
by a graph set motif [25] of C(8). Each H2O molecule forms two intermolecular H-
bonds with the oxide O-atoms of two C2-related zwitterionic molecules, thereby 
crosslinking the two directions of the extended chains into two-dimensional networks, 
which lie parallel to the (001) plane. 
 
According to [14], treatment of imidazole 3-oxides of type 11 in CH2Cl2 with 
Ac2O led to their isomerization to imidazol-2-ones, even at 0–5o. Heating of solutions of 
imidazol-2-ones in Ac2O resulted in the acetylation of N(3) [14]. In the case of 11b,c, 
and e, the reaction with excess Ac2O at 0o to room temperature resulted not only in the 
isomerization but also in acetylation of the OH group to yield the corresponding 
acetates 13 (Scheme 3). In none of the cases was acetylation of N(3) observed. In the IR 
as well as in the 13C-NMR spectra, the presence of an ester and a urea C=O group is 
evidenced by absorptions at ca. 1740 and 1670 cm–1 and 170 and 155 ppm, respectively. 
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Scheme 3 
 
In analogy to previously reported transformations of 2-unsubstituted imidazole 
3-oxides [12], compounds 11a and 11e, respectively, reacted easily with 2,2,4,4-
tetramethylcyclobutane-1,3-dithione to give the corresponding imidazole-2-thiones 14a 
and 14b in high yield (Scheme 3).  
Due to the fact that bis-imidazoles are of interest in the field of coordination 
chemistry [11], reactions of alkanediamines 15 with aldehydes and 10 were carried out 
in refluxing EtOH. In the case of formaldehyde used in excess (2.5 equiv.), the three-
component reaction yielded 2-unsubstituted products 16 with a variable length of the 
aliphatic chain, which connects the two imidazole residues (Scheme 4, Table 2). The 
reaction with ethane-1,2-diamine (15a), 10b, and acetaldehyde gave the expected bis-
(imidazole 3-oxide) 16c with the Me group at C(2) of the imidazole. 
 
Scheme 4 
 
Table 2. Prepared Bis-(imidazole 3-Oxides) 16. 
 
The spectroscopic data confirm the structures of the bis-(imidazole 3-oxides) 16, 
and in the case of 16b, the structure has been established by X-ray crystallography (Fig. 
2). The heterocyclic molecule has crystallographic C2 symmetry. The asymmetric unit 
includes a H2O molecule in a general position so that the ratio of heterocyclic molecules 
to H2O is 1:2. The two oxide O-atoms in each bis-imidazole molecule are bridged by a 
pair of intermolecular H-bonds from each of two H2O molecules. Thus, two H2O 
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molecules and the two oxide O-atoms from a single heterocyclic molecule combine to 
form a C2-symmetric H-bonded loop with a graph set motif of R2,4(8). 
 
Fig. 2. ORTEP-Plot [24] of the molecular structure of 16b (arbitrary numbering of the 
atoms, 50% probability ellipsoids, the H2O molecule is not shown) 
 
It is worth mentioning that the attempted synthesis of a 1-(2-
aminoethyl)imidazole 3-oxide from 15a, formaldehyde, and 10a in a ratio of 1:1:1 did 
not afford the expected product and, again, 16a was obtained. As an alternative method, 
monoacetylated diamines 17 were reacted with formaldehyde, and the crude imines 
obtained thereby were heated together with 10 in EtOH. Under these conditions, 
imidazole 3-oxides of type 18 were formed and isolated as crystalline materials (Scheme 
4). 
The reactivity of bis-(imidazole 3-oxides) of type 16 toward Ac2O was tested 
using 16a. The isomerization to give the bis-(imidazole-2-one) 19 was achieved by 
heating 16a in a 1:1 mixture of CHCl3 and Ac2O under reflux for 3 h (Scheme 5). On 
the other hand, heating of 16a in boiling Ac2O resulted in complete acetylation of the 
rearranged product, and 20a was obtained in fair yield (Scheme 5). The analogous 
reaction sequence was observed with 16e and 16f. 
 
Scheme 5 
 
The conversion of 2-unsubstituted imidazole 3-oxides to imidazole-2-thiones 
using 2,2,4,4-tetramethylcyclobutane-1,3-dithione (cf. Scheme 3) was applied efficiently 
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in the case of 16e. The reaction was carried out in CHCl3 at room temperature, and the 
bis-(imidazole-2-thione) 21 precipitated from the solution (Scheme 6). 
 
Scheme 6 
 
Finally, the deoxygenation of 16f with Raney-Ni in EtOH led to the bis-
imidazole derivative 22 (Scheme 6). 
 
3. Conclusion. – 
The present study shows that the synthesis of 2-unsubstituted imidazole 3-oxides 
based on the three-component reaction of an α-(hydroxyimino)ketone, formaldehyde, 
and an amino component is a convenient and efficient access to new derivatives derived 
from aminoalcohols and diamines. In the case of enantiomerically pure aminoalcohols, 
optically active products are formed without any racemization. The readily available 
bis-imidazole derivatives obtained from aliphatic α,ω-diamines are attractive ligands for 
the preparation of new metal complexes. 
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financial support.  
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Experimental Part 
1. General. M.p.: Melt-Temp. II apparatus (Aldrich), in capillary; uncorrected. 
IR: NEXUS FT-IR spectrophotometer, in KBr; in cm–1. 1H- and 13C-NMR: Tesla 
BS567A (80 and 20 MHz, resp.) or Bruker AC 300 instrument (300 and 75.5 MHz, 
resp.), in CDCl3, CD3OD or (D6)DMSO; TMS as an internal standard. The multiplicity 
of the 13C-NMR signals was deduced from the DEPT spectra. MS (EI, ESI or CI): 
Finnigan MAT-90 or Finnigan SSQ-700 instruments. Elemental analyses were 
performed in the Analytical Laboratory of the University of Zürich. 
2. Starting materials. α-(Hydroxyimino)ketones 10 were obtained according to 
known protocols: butane-2,3-dione monooxime (10a) [26a], 1-phenylpropane-1,2-dione 
1-oxime (10b) [26b] and 1-phenylpropane-1,2-dione 2-oxime (10c) [26c] by nitrosation 
of the corresponding ketones using isoamyl nitrate, 1,2-diphenylethane-1,2-dione 
monooxime (benzil monooxime, 10d) [26d] from dibenzoyl (benzil) and hydroxylamine 
hydrochloride.  
3. Preparation of 1,3,5-Trisubstituted-1,2,3,4,5,6-hexahydro-1,3,5-triazines 12. 
Prepared analogously to a known protocol [22] from the following amines: 2-
aminoethan-1-ol (9a), 3-aminopropan-1-ol (9b), 1-aminopropan-2-ol (9c), 2-
aminobutan-1-ol ((RS)-9d), (+)-(S)-1-aminopropan-2-ol ((S)-9c), and (+)-(1S,2S)-2-
amino-1-phenylpropane-1,3-diol ((S,S)-9e), respectively. In a standard procedure, to the 
soln. of the corresponding aminoalcohol (0.10 mol) in MeOH (100 ml), 0.11 mol of 
paraformaldehyde was added and the resulting suspension was stirred overnight. Then, 
the excess of paraformaldehyde was filtered and the filtrate was concentrated in vacuo 
to give 12 as a colorless or pale yellow oil in quantitative yield. The crude products 12 
were used in the next step without purification. 
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4. Synthesis of 1-Hydroxyalkylimidazole 3-Oxides 11. A soln. of 10 mmol of 
dione monooxime (10a–d) and 12 mmol of the corresponding 12 in abs. EtOH was 
heated for 3 h. After evaporation of the solvent under reduced pressure, the resulting oil 
was washed twice with Et2O, treated with acetone, and cooled. The product was 
obtained as a white solid, usually as a hydrate with a variable amount of H2O. Samples 
for analysis were recrystallized from appropriate solvents. In the case of 11e,g, and l, 
the resulting mixtures were purified by column chromatography (CC). 
1-(2-Hydroxyethyl)-4,5-dimethyl-1H-imidazole 3-Oxide (11a). Yield3): 145 mg 
(88%). Colorless solid. M.p. 106–107º (CHCl3/hexane). IR: 3470–2700vs (br.), 1626m, 
1447m, 1404s, 1386m, 1346s, 1324s, 1194m, 1149m, 1092s, 1075s, 830m, 755m, 630s, 
607s. 1H-NMR (CDCl3): 7.95 (s, H–C(2)); 3.88, 3.85 (2t, 2 CH2); 2.14, 2.11 (2s, 2 Me). 
13C-NMR (CDCl3): 125.9, 121.6 (2s, C(4), C(5)); 125.8 (d, C(2)); 60.3, 48.5 (2t, 2 
CH2); 8.7, 7.1 (2q, 2 Me). CI-MS: 157 (17, [M+1]+), 141 (100). Anal. calc. for 
C7H12N2O2 · 0.5 H2O (165.20): C 50.90, H 7.93, N 16.96; found C 50.88, H 7.50, N 
17.08.  
Suitable crystals for an X-ray crystal structure determination were grown from 
CHCl3/hexane by slow evaporation of the solvent at r.t. 
1-(2-Hydroxyethyl)-5-methyl-4-phenyl-1H-imidazole 3-Oxide (11b). Yield3): 
177 mg (81%). Colorless crystals. M.p. 186–188º (CHCl3/hexane). IR: 3350–2800vs 
(br.), 1614m, 1442m, 1389m, 1382m, 1353s, 1249m, 1213m, 1055vs, 770s, 716s, 699s, 
608s. 1H-NMR (CDCl3): 8.27 (s, H–C(2)); 7.55–7.34 (m, 5 arom. H); 4.05, 3.84 (2t, 2 
CH2); 2.27 (s, Me). 13C-NMR (CDCl3): 129.7, 128.7, 128.3 (3d, 5 arom. CH); 129.4 (s, 
arom. Cq); 127.0, 126.2 (2s, C(4), C(5)); 123.4 (d, C(2)); 59.8, 48.5 (2t, 2 CH2); 9.2 (q, 
                                                          
3) Yield before crystallization. 
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Me). EI-MS: 218 (12, M+.), 202 (100), 158 (46), 103 (56), 77 (27). Anal. calc. for 
C12H14N2O2 (218.26): C 66.04, H 6.47, N 12.84; found C 66.15, H 6.35, N 12.42. 
1-(2-Hydroxyethyl)-4,5-diphenyl-1H-imidazole 3-Oxide (11c). Yield3): 251 mg 
(89%). Colorless solid. M.p. 197–198º (CHCl3/petroleum ether). IR: 3350–2600vs (br.), 
1443m, 1393m, 1350s, 1200m, 1076m, 844m, 772s, 753vs, 694s, 658m. 1H-NMR 
(CDCl3): 8.46 (s, H–C(2)); 7.49–7.23 (m, 10 arom. H); 4.01, 3.71 (2t, 2 CH2). 13C-NMR 
(CDCl3): 130.7, 129.7, 129.5, 129.0, 128.5, 128.0 (6d, 10 arom. CH); 129.8, 127.7, 
126.4, 125.7 (4s, 2 arom. Cq, C(4), C(5)); 127.6 (d, C(2)); 59.9, 48.6 (2t, 2 CH2). EI-
MS: 280 (31, M+.), 264 (100), 219 (48), 165 (68), 103 (71), 77 (57). Anal. calc. for 
C17H16N2O2 · 0.1 H2O (282.13): C 72.37, H 5.79, N 9.93; found C 72.34, H 5.71, N 
9.64.  
1-(2-Hydroxyethyl)-4-methyl-5-phenyl-1H-imidazole 3-Oxide (11d). Yield3): 
120 mg (55%). Colorless solid. M.p. 165–167º (acetone). IR: 3250–2550vs (br.), 
1501m, 1444m, 1395s, 1380m, 1337vs, 1165s, 1080s, 871m, 757s, 703s, 646m. 1H-
NMR (CDCl3): 8.36 (s, H–C(2)); 7.56–7.42 (m, 5 arom. H); 4.02, 3.62 (2t, 2 CH2); 2.15 
(s, Me). 13C-NMR (CDCl3): 130.8, 129.6, 129.3 (3d, 5 arom. CH); 127.8, 127.4, 126.8 
(3s, arom. Cq, C(4), C(5)); 60.5, 49.1 (2t, 2 CH2); 7.6 (q, Me). EI-MS: 218 (76, M+.), 
202 (100), 130 (63), 104 (72). Anal. calc. for C12H14N2O2 (218.26): C 66.04, H 6.47, N 
12.84; found C 66.38, H 6.43, N 12.46 
1-(3-Hydroxypropyl)-5-methyl-4-phenyl-1H-imidazole 3-Oxide (11e). Yield after 
CC (Rf = 0.59, SiO2, AcOEt/MeOH 6:4): 218 mg (94%). Colorless solid. M.p. 140–142º 
(acetone). IR: 3350–2550vs (br.), 1497m, 1467m, 1400m, 1363s, 1344s, 1315m, 1253s, 
1231m, 1064s, 930m, 766s, 712s, 702s, 695s, 608s. 1H-NMR (CD3OD): 8.31 (s, H–
C(2)); 7.59–7.40 (m, 5 arom. H); 4.14, 3.59 (2t, 2 CH2); 2.29 (s, Me); 1.99 (m, CH2). 
13C-NMR (CD3OD): 131.1, 129.8, 129.5 (3d, 5 arom. CH); 130.6, 128.2, 125.2 (3s, 
 13 
arom. Cq, C(4), C(5)); 127.8 (d, C(2)); 58.9, 44.0, 33.7 (3t, 3 CH2); 9.2 (q, Me). EI-MS: 
232 (5, M+.), 214 (100), 117 (47), 55 (49). Anal. calc. for C13H16N2O2 (232.28): C 
67.22, H 6.94, N 12.06; found C 67.46, H 7.06, N 11.70. 
1-(3-Hydroxypropyl)-4,5-diphenyl-1H-imidazole 3-Oxide (11f). Yield3): 140 mg 
(47%). Colorless solid. M.p. 191–193º (acetone). IR: 3350–2650vs (br.), 1445m, 1392s, 
1345s, 1198m, 1078s, 769s, 756s, 698s, 657m. 1H-NMR (CD3OD): 8.51 (s, H–C(2)); 
7.48–7.26 (m, 10 arom. H); 4.09, 3.48 (2t, 2 CH2); 1.81 (m, CH2). 13C-NMR (CD3OD): 
132.1, 131.2, 130.9, 130.3, 129.7, 129.2, 128.9 (7d, 10 arom. CH, C(2)); 131.4, 129.3, 
128.5, 127.8 (4s, 2 arom. Cq, C(4), C(5)); 59.0, 44.8, 33.8 (3t, 3 CH2). EI-MS: 294 (7, 
M+.), 276 (75), 165 (19), 117 (100), 104 (19), 77 (22). Anal. calc. for C18H18N2O2 · 0.25 
H2O (298.86): C 72.34, H 6.24, N 9.37; found C 72.26, H 6.08, N 9.30. 
1-(3-Hydroxypropyl)-4-methyl-5-phenyl-1H-imidazole 3-Oxide (11g). Yield after 
CC (Rf = 0.65, SiO2, AcOEt/MeOH 1:1): 153 mg (66%). Colorless solid. M.p. 139–140º 
(CH2Cl2/petroleum ether). IR: 3250–2650vs (br.), 1463m, 1389m, 1379m, 1325s, 1165s, 
1091m, 1076m, 942w, 773s, 705m, 643m. 1H-NMR (CD3OD): 8.37 (s, H–C(2)); 7.56–
7.40 (m, 5 arom. H); 4.07, 3.43 (2t, 2 CH2); 1.76 (m, CH2). 13C-NMR (CD3OD): 131.5, 
130.8, 130.3 (3d, 5 arom. CH); 128.5, 128.4, 127.4 (3s, arom. Cq, C(4), C(5)); 128.0 (d, 
C(2)); 58.9, 44.6, 33.8 (3t, 3 CH2); 7.6 (q, Me). EI-MS: 232 (22, M+.), 214 (100), 171 
(52), 117 (76), 104 (29), 55 (29). Anal. calc. for C13H16N2O2 (232.28): C 67.22, H 6.94, 
N 12.06; found C 67.37, H 7.05, N 12.01. 
1-(2-Hydroxypropyl)-5-methyl-4-phenyl-1H-imidazole 3-Oxide (11h). Yield3): 
211 mg (90%). Colorless solid. M.p. 143–145º (acetone). IR: 3400–2600vs (br.), 
1610m, 1497m, 1444m, 1377s, 1349s, 1260m, 1218m, 1136m, 1079m, 1029m, 767s, 
720m, 700s, 678m, 608m. 1H-NMR (CD3OD): 8.25 (s, H–C(2)); 7.58–7.37 (m, 5 arom. 
H); 4.07–4.01 (m, CH2); 3.87–3.82 (m, -CH(OH)-); 2.28 (s, Me); 1.22 (d, J = 4.6, Me). 
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13C-NMR (CD3OD): 131.2, 129.7, 129.5 (3d, 5 arom. CH); 130.4, 128.3, 125.7 (3s, 
arom. Cq, C(4), C(5)); 128.4 (d, C(2)); 67.3 (d, CH); 53.8 (t, CH2); 20.7, 9.5 (2q, 2 Me). 
EI-MS: 232 (62, M+.), 216 (100), 174 (64), 159 (72), 130 (40), 103 (58). Anal. calc. for 
C13H16N2O2 · 0.125 H2O (234.53): C 66.58, H 6.98, N 11.94; found C 66.89, H 6.98, N 
11.82. 
1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazole 3-Oxide (11i). Yield3): 274 mg 
(92%). Colorless solid. M.p. 182–184º (CH2Cl2/petroleum ether). IR: 3350–2550vs 
(br.), 1486m, 1445m, 1398m, 1353s, 1265m, 1187m, 1138m, 763s, 701s, 656m. 1H-
NMR (CD3OD): 8.48 (s, H–C(2)); 7.45–7.28 (m, 10 arom. H); 3.99–3.77 (m, CH2, CH); 
1.04 (d, J = 4.2, Me). 13C-NMR (CD3OD): 132.3, 131.2, 130.9, 130.2, 129.7, 129.1 (6d, 
10 arom. CH); 131.0, 129.2, 128.4, 127.8 (4s, 2 arom. Cq, C(4), C(5)); 129.3 (d, C(2)); 
66.8 (d, CH); 54.2 (t, CH2); 20.7 (q, Me). EI-MS: 294 (2, M+.), 278 (11), 105 (100), 77 
(35), 43 (46). Anal. calc. for C18H18N2O2 · 0.25 H2O (298.86): C 72.34, H 6.24, N 9.37; 
found: C 72.29, H 6.24, N 8.98. 
1-((2S)-2-Hydroxypropyl)-4,5-dimethyl-1H-imidazole 3-Oxide (11j). Yield after 
CC (Rf = 0.59; SiO2, AcOEt/MeOH 6:4): 141 mg (82%). Colorless solid. M.p. 119–120º 
(acetone). [α] 17D  +42 (c = 1, MeOH). IR: 3350–2600vs (br.), 1629m, 1446m, 1430m, 
1398s, 1380m, 1340s, 1331s, 1303m, 1190m, 1139s, 1116m, 1081m, 864m, 839m, 
684m. 1H-NMR (CDCl3): 7.84 (s, H–C(2)); 4.20–3.68 (m, CH); 3.75 (d, J = 2.9, CH2); 
2.13, 2.09 (2s, 2 Me); 1.21 (d, J = 6.1, Me). 13C-NMR (CD3OD): 127.4 (d, C(2)); 126.4, 
124.1 (2s, C(4), C(5)); 67.2 (d, CH); 53.5 (t, CH2); 20.7, 8.7, 7.1 (3q, 3 Me). CI-MS: 
171 (14, [M+1]+), 155 (100), 153 (13). Anal. calc. for C8H14N2O2 · 0.125 H2O (172.46): 
C 55.72, H 8.33, N 16.24; found C 55.60, H 8.33, N 16.44. 
1-[1-(Hydroxymethyl)propyl]-5-methyl-4-phenyl-1H-imidazole 3-Oxide (11k). 
Yield3): 212 mg (86%). Colorless solid. M.p. 171–174º (CH2Cl2/petroleum ether). IR: 
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3250–2550vs (br.), 1496m, 1443m, 1419m, 1351s, 1327m, 1227s, 1082m, 765s, 700s. 
1H-NMR (CDCl3): 8.38 (s, H–C(2)); 7.59–7.42 (m, 5 arom. H); 4.28–4.16 (m, CH); 3.80 
(d, J = 4.0, CH2OH); 2.30 (s, Me); 1.94–1.85 (m, CH2); 0.94 (t, J = 5.5, Me). 13C-NMR 
(CD3OD): 131.3, 129.7, 129.5 (3d, 5 arom. CH); 130.1, 128.2, 126.0 (3s, arom. Cq, 
C(4), C(5)); 126.1 (d, C(2)); 64.8, 25.4 (2t, 2 CH2); 62.0 (d, CH); 10.7, 9.7 (2q, 2 Me). 
EI-MS: 246 (22, M+.), 215 (15), 174 (100), 130 (16), 104 (19), 77(16). Anal. calc. for 
C14H18N2O2 (246.31): C 68.27, H 7.37, N 11.37; found C 68.00, 7.38, 11.50. 
1-[1-(Hydroxymethyl)propyl]-4,5-diphenyl-1H-imidazole 3-Oxide (11l). Yield3): 
219 mg (71%). Colorless solid. M.p. 199–200º (acetone). IR: 3300–2600vs (br.), 
1604m, 1506m, 1486m, 1445m, 1410m, 1350s, 1239m, 1079m, 1064m, 759s, 696s, 
655m, 645m. 1H-NMR (CDCl3): 8.34 (s, H–C(2)); 7.58–7.05 (m, 10 arom. H); 4.08–
3.61 (m, CH); 3.67 (d, J = 4.8, CH2OH); 1.91–1.47 (m, CH2); 0.68 (t, J = 7.2, Me). 13C-
NMR (CD3OD): 132.7, 131.1, 130.9, 130.1, 129.6, 129.1 (6d, 10 arom. CH); 130.7, 
130.4, 128.5, 127.8 (4s, 2 arom. Cq, C(4), C(5)); 126.8 (d, C(2)); 64.7, 25.8 (2t, 2 CH2); 
62.2 (d, CH); 10.7 (q, Me). EI-MS: 308 (29, M+.), 292 (25), 236 (100), 165 (22), 104 
(37). 
1-((1S,2S)-2-Hydroxy-1-hydroxymethyl-2-phenylethyl)-5-methyl-4-phenyl-1H-
imidazole 3-Oxide (11m). Yield after CC (Rf = 0.7, SiO2, MeOH): 168 mg (52%). 
Colorless solid. M.p. 177–178º (CH2Cl2/petroleum ether). [α] 17D  +137 (c = 0.38, 
MeOH). IR: 3450–2450vs (br.), 1625m, 1497m, 1452m, 1412m, 1356s, 1232m, 1093m, 
1066m, 1047m, 1029m, 764m, 739m, 699s. 1H-NMR (CD3OD): 8.48 (s, H–C(2)); 7.46–
7.25 (m, 10 arom. H); 5.16, 5.15 (d, CHOH); 4.39–4.36 (m, CH); 4.02, 4.01 (d, CH2); 
1.69 (s, Me). 13C-NMR (CD3OD): 131.2, 129.7, 129.6, 129.4, 129.1, 127.1 (6d, 10 
arom. CH); 142.8, 128.1, 127.2, 126.7 (4s, 2 arom. Cq, C(4), C(5)); 127.3 (d, C(2)); 
72.9, 65.9 (2d, 2 CH); 63.2 (t, CH2); 9.1 (q, Me). EI-MS: 324 (2, M+.), 200 (100), 104 
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(21), 77 (22). Anal. calc. for C19H20N2O3 (324.38): C 70.35, H 6.21, N 8.64; found C 
70.51, H 6.25, N 8.74. 
5. General Procedure for Synthesis of Acetates 13. To a soln. of 1 mmol of 1H-
imidazole N-oxide 11 in abs. CH2Cl2 (2 ml) in a H2O/ice cooling bath, a soln. of freshly 
distilled Ac2O (0.61 g, 6 mmol) in abs. CH2Cl2 (2 ml) was added portion-wise. The 
mixture was allowed to warm up to r.t., and stirring was continued until 11 had been 
consumed (TLC monitoring). Then, the mixture was diluted with MeOH (5 ml). After 
stirring for another 30 min, the solvents were evaporated, H2O (5 ml) was added, and 
the white precipitate of the corresponding acetate 13 was filtered. Analytically pure 
products were obtained by recrystallization. 
2-(2,3-Dihydro-5-methyl-2-oxo-4-phenylimidazol-1-yl)ethyl Acetate (13a). 
Reaction time 2 h. Yield: 185 mg (71%). Colorless solid. M.p. 135–137° (EtOH/H2O). 
IR: 3150–2750s (br., NH), 1745vs (C=O(Ac)), 1672vs (br., C=O), 1456m, 1429m, 
1403m, 1388m, 1367m, 1255s, 1240s, 1070m, 769m, 750m, 702m. 1H-NMR (CDCl3): 
10.89 (br. s, NH); 7.44–7.21 (m, 5 arom. H); 4.30, 3.93 (2t, 2 CH2); 2.25, 2.01 (2s, 2 
Me). 13C-NMR (CDCl3): 170.7 (s, C=O(Ac)); 154.6 (s, C=O(imidazole)); 130.5, 118.2, 
115.6 (3s, arom. Cq, C(4), C(5)); 128.8, 126.7, 126.3 (3d, 5 arom. CH); 62.5, 39.7 (2t, 2 
CH2); 20.8, 9.8 (2q, 2 Me). CI-MS: 261 (100, [M+1]+). Anal. calc. for C14H16N2O3 
(260.30): C 64.60, H 6.20, N 10.76; found: C 64.27, H 5.98, N 10.51. 
2-(2,3-Dihydro-2-oxo-4,5-diphenylimidazol-1-yl)ethyl Acetate (13b). Reaction 
time 2 h. Yield: 303 mg (94%). Colorless solid. M.p. 187–190° (EtOH). IR: 3200–
2750s (br., NH), 1739s (C=O(Ac)), 1686vs (br., C=O), 1602m, 1506m, 1454m, 1444m, 
1432m, 1395m, 1370m, 1234s, 1045m, 768m, 753m, 701m, 667m. 1H-NMR (CDCl3): 
11.69 (br. s, NH); 7.47–7.11 (m, 10 arom. H); 4.18, 3.88 (2t, 2 CH2); 1.89 (s, Me). 13C-
NMR (CDCl3): 170.6 (s, C=O(Ac)); 154.7 (s, C=O(imidazole)); 131.2, 129.2, 129.0, 
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128.5, 126.8, 125.7 (6d, 10 arom. CH); 129.7, 129.6, 120.7, 119.2 (4s, 2 arom. Cq, C(4), 
C(5)); 62.1, 40.1 (2t, 2 CH2); 20.8 (q, Me). CI-MS: 323 (100, [M+1]+), 263 (5). Anal. 
calc. for C19H18N2O3 (322.37): C 70.79, H 5.63, N 8.69; found: C 70.80, H 5.76, N 8.72. 
3-(2,3-Dihydro-5-methyl-2-oxo-4-phenylimidazol-1-yl)propyl Acetate (13c). 
Reaction time 3 h. Yield: 200 mg (73%). Colorless solid. M.p. 153–154º (EtOH). IR: 
3200–2850s (br., NH), 1734vs (C=O(Ac)), 1675vs (br., C=O), 1603m, 1503w, 1465m, 
1404m, 1388m, 1364m, 1254s, 1042m, 767m, 747m, 699m. 1H-NMR (CDCl3): 10.64 
(br. s, NH); 7.29–7.10 (m, 5 arom. H); 3.99, 3.64 (2t, 2 CH2); 2.10, 1.90 (2s, 2 Me); 1.88 
(m, CH2). 13C-NMR (CDCl3): 170.9 (s, C=O(Ac)); 154.0 (s, C=O(imidazole)); 130.2, 
118.3, 115.5 (3s, arom. Cq, C(4), C(5)); 128.7, 126.8, 126.3 (3d, 5 arom. CH); 61.8, 
38.0, 28.5 (3t, 3 CH2); 20.8, 9.6 (2q, 2 Me). EI-MS: 275 (16, [M+1]+), 274 (100, M+.), 
215 (66), 174 (36), 101 (63), 77 (18). Anal. calc. for C15H18N2O3 (274.32): C 65.68, H 
6.61, N 10.21; found: C 66.08, H 6.63, N 10.01. 
6. Preparation of 1,3-Dihydroimidazole-2-thiones 14. To a soln. of an imidazole 
N-oxide 11 (1 mmol) in MeOH (2 ml), a soln. of 2,2,4,4-tetramethylcyclobutane-1,3-
dithione (95 mg, 0.55 mmol) in CHCl3 (2 ml) was added drop-wise at 0°, and 
magnetical stirring was continued for 30 min. Then, the solvents were evaporated i.v., 
the resulting solid was washed with Et2O, and the colorless product was filtered and 
dried i.v. Analytically pure samples were obtained by recrystallization from appropriate 
solvent. 
1,3-Dihydro-1-(2-hydroxyethyl)-4,5-dimethylimidazole-2-thione (14a). Yield: 
148 mg (86%). Colorless crystals. M.p. 179–180° (MeOH). IR: 3350–2750vs (br., NH), 
1659m, 1506m, 1444m, 1402s, 1363m, 1224w, 1186w, 1058s, 870w. 1H-NMR 
((D6)DMSO): 3.92, 3.61 (2t, 2 CH2); 2.06, 1.96 (2s, 2 Me). 13C-NMR ((D6)DMSO): 
168.3 (s, C=S); 131.3, 127.8 (2s, C(4), C(5)); 68.1, 55.6 (2t, 2 CH2); 18.1, 18.0 (2q, 2 
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Me). EI-MS: 172 (92, M+.), 128 (100), 95 (39). Anal. calc. for C7H12N2OS (127.25): C 
48.81, H 7.02, N 16.26; found: C 49.11, H 7.06, N 15.70. 
1,3-Dihydro-1-(3-hydroxypropyl)-5-methyl-4-phenylimidazole-2-thione (14b). 
Yield: 231 mg (93%). Colorless crystals. M.p. 172–174º (CH2Cl2/petroleum ether). IR: 
3350–2750vs (br., NH), 1497s, 1459m, 1407s, 1376m, 1282m, 1213m, 1196m, 1174s, 
1087m, 1068s, 985m, 933m, 769s, 708m, 699s. 1H-NMR ((D6)DMSO): 12.42 (br.s, 
NH); 7.48–7.31 (m, 5 arom. H); 4.08, 3.46 (2t, 2 CH2); 2.31 (s, Me); 1.83 (m, CH2). 13C-
NMR ((D6)DMSO): 169.9 (s, C=S); 138.4 (s, arom. Cq); 138.3, 136.9, 136.4 (3d, 5 
arom. CH); 133.0, 132.1 (2s, C(4), C(5)); 67.4, 50.6, 40.9 (3t, 3 CH2); 19.2 (q, Me). EI-
MS: 248 (41, M+.), 230 (59), 215 (100), 204 (27). Anal. calc. for C13H16N2OS (248.35): 
C 62.87, H 6.49, N 11.28; found: C 62.90, H 6.48, N 11.10. 
7. Preparation of 1,1’-(Alkane-1,n-diyl)bisimidazole 3,3’-Dioxides 16. A soln. of 
a diamine 15 (1 mmol), paraformaldehyde (75 mg, 2.5 mmol) or acetaldehyde (110 mg, 
2.5 mmol) and 10 (2 mmol) in EtOH was heated to reflux for 3 h. Then, the solvent was 
evaporated i.v. To the resulting oil, acetone (10 ml) was added, the soln. was heated to 
reflux, and after cooling, the colorless precipitate was collected as highly pure product. 
1,1’-(Ethane-1,2-diyl)bis(4,5-dimethylimidazole) 3,3’-Dioxide (16a). Yield: 137 
mg (48%). Colorless solid. M.p. (dec.) 231–236° (EtOH/Et2O). IR: 3650–2800vs (br.), 
1629m, 1451m, 1400s, 1386s, 1358m, 1336s, 1154m, 834m, 790m, 620m, 603m. 1H-
NMR (CDCl3): 8.15 (s, H–C(2), H–C(2’)); 4.33 (s, 2 CH2); 2.13, 1.99 (2s, 4 Me). 13C-
NMR (CDCl3): 127.5, 124.1 (2s, C(4), C(4’), C(5), C(5’)); 127.1 (d, C(2), C(2’)); 46.7 
(t, 2 CH2); 7.9, 7.1 (2q, 4 Me). ESI-MS: 273 (100, [M+Na]+), 251 (2, [M+1]+). Anal. 
calc. for C12H18N4O2 · 2 H2O (286.34): C 50.34, H 7.74, N 19.57; found C 50.05, H 
8.34, N 19.68. 
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1,1’-(Ethane-1,2-diyl)bis(5-methyl-4-phenylimidazole) 3,3’-Dioxide (16b). 
Yield: 172 mg (42%). Colorless crystals. M.p. (dec.) 236–240° (MeOH/EtOH). IR: 
3550–2700vs (br.), 1679m, 1498m, 1399s, 1361m, 1344m, 1268m, 1228m, 764s, 707m, 
697m, 628m, 601m. 1H-NMR (CD3OD): 8.68 (s, H–C(2), H–C(2’)); 7.85–7.67 (m, 10 
arom. H); 4.73 (s, 2 CH2); 2.37 (s, 2 Me). 13C-NMR (CD3OD): 131.3, 127.2, 125.4 (3s, 
2 arom. Cq, C(4), C(4’), C(5), C(5’)); 131.1, 130.1, 129.6 (3d, 10 arom. CH); 127.9 (d, 
C(2), C(2’)); 46.9 (t, 2 CH2); 8.9 (q, 2 Me). ESI-MS: 397 (100, [M+Na]+), 375 (6, 
[M+1]+). Anal. calc. for C22H22N4O2 · 2 H2O (410.49): C 64.38, H 6.38, N 13.65; found: 
C 64.32, H 6.33, N 13.60.  
Suitable crystals for the X-ray crystal structure determination were grown from 
EtOH by slow evaporation of the solvent at r.t. 
1,1’-(Ethane-1,2-diyl)bis(2,5-dimethyl-4-phenylimidazole) 3,3’-Dioxide (16c). 
Yield: 153 mg (35%). Colorless solid. M.p. (dec.) 234–237° (acetone). IR: 3450–2850vs 
(br.), 1626m, 1516m, 1490m, 1462m, 1445m, 1414m, 1382m, 1348s, 1318m, 1274s, 
1224m, 769s, 703s, 656m, 597s. 1H-NMR (CD3OD): 7.52–7.38 (m, 10 arom. H); 4.35 
(s, 2 CH2); 2.48, 2.05 (2s, 4 Me). 13C-NMR (CD3OD): 134.5, 130.0, 126.7, 121.9 (4s, 2 
arom. Cq, C(2), C(2’), C(4), C(4’), C(5), C(5’)); 130.2, 129.4, 128.9 (3d, 6 arom. CH); 
44.2 (t, CH2); 8.7, 7.9 (2q, 4 Me). EI-MS: 402 (22, M+.), 386 (36), 355 (100), 213 (33), 
172 (56), 103 (52). Anal. calc. for C24H26N4O2 · 2 H2O (438.54): C 65.73, H 6.90, N 
12.78; found: C 66.23, H 6.89, N 12.53. 
1,1’-(Propane-1,3-diyl)bis(4,5-dimethylimidazole) 3,3’-Dioxide (16d). Yield: 33 
mg (11%). Colorless solid. M.p. (dec.) 191–196º. IR: 3550–2800vs (br.), 1686m, 
1626m, 1472m, 1403m, 1380s, 1345s, 1200m, 1149m, 1077m, 695m, 618m, 582m. 1H-
NMR (CD3OD): 8.22 (s, H–C(2), H–C(2’)); 4.02 (t, 2 CH2); 2.23 (m, CH2); 2.20, 2.14 
(2s, 4 Me). 13C-NMR (CD3OD): 127.2, 126.8 (2s, C(4), C(4’), C(5), C(5’)); 123.7 (d, 
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C(2), C(2’)); 43.8, 31.7 (2t, 3 CH2); 8.3, 7.0 (2q, 4 Me). EI-MS: 264 (3, M+.), 232 (26), 
137 (51), 123 (100), 110 (93), 96 (57). Anal. calc. for C13H20N4O2 · 2 H2O (300.37): C 
51.99, H 8.05, N 18.65; found: C 51.70, H 8.12, N 17.75. 
1,1’-(Butane-1,4-diyl)bis(4,5-dimethylimidazole) 3,3’-Dioxide (16e). Yield: 156 
mg (47%). Colorless solid. M.p. (dec.) 151–155° (EtOH). IR (KBr): 3550–2850vs (br.), 
1625m, 1401m, 1377m, 1341s, 1228m, 1160m, 1142m, 682m, 625m. 1H-NMR 
(CD3OD): 8.19 (s, H–C(2), H–C(2’)); 4.00 (t, 2 CH2); 2.20, 2.14 (2s, 4 Me); 1.81–1.75 
(m, 2 CH2). 13C-NMR (CD3OD): 127.0, 123.6 (2s, C(4), C(4’), C(5), C(5’)); 126.7 (d, 
C(2), C(2’)); 46.2, 28.1 (2t, 4 CH2); 8.4, 7.1 (2q, 4 Me). ESI-MS: 279 (100, [M+1]+). 
Anal. calc. for C14H22N4O2 · 3 H2O (332.42): C 50.59, H 8.49, N 16.86; found: C 50.40, 
H 8.18, N 16.50. 
1,1’-(Hexane-1,6-diyl)bis(4,5-dimethylimidazole) 3,3’-Dioxide (16f). Yield: 162 
mg (43%). Colorless solid. M.p. (dec.) 101–104° (EtOH/Et2O). IR: 3500–2950vs (br.), 
1627m, 1481m, 1413m, 1381m, 1336m, 1193m, 1144m, 1088m, 738m, 589m. 1H-NMR 
(CDCl3): 7.89 (s, H–C(2), H–C(2’)); 3.84 (t, 2 CH2); 2.15 (br. s, 4 Me); 1.82–1.66, 
1.40–1.29 (2m, 4 CH2). 13C-NMR (CDCl3): 127.1 (d, C(2), C(2’)); 126.0, 121.2 (2s, 
C(4), C(4’), C(5), C(5’)); 45.4, 29.8, 25.6 (3t, 6 CH2); 8.2, 6.3 (2q, 4 Me). EI-MS: 306 
(21, M+.), 290 (47), 273 (51), 179 (59), 165 (100), 151 (66), 137 (56), 110 (70). Anal. 
calc. for C16H26N4O2 · 4 H2O (378.49): C 50.78, H 9.06, N 14.80; found: C 50.39, H 
9.15, N 14.40. 
1,1’-(Hexane-1,6-diyl)bis(5-methyl-4-phenylimidazole) 3,3’-Dioxide (16g). 
Yield: 247 mg (53%). Colorless solid. M.p. (dec.) 188–192° (EtOH/Et2O). IR: 3600–
2750vs (br.), 1646m, 1497m, 1470m, 1429m, 1390s, 1365s, 1347s, 1250m, 1216m, 
835m, 762s, 699s, 598s. 1H-NMR (CD3OD): 8.34 (s, H–C(2), H–C(2’)); 7.60–7.37 (m, 
10 arom. H); 4.04 (t, 2 CH2); 2.28 (s, 2 Me); 1.84 (t, 2 CH2); 1.49–1.44 (m, 2 CH2). 13C-
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NMR (CD3OD): 131.1, 129.7, 129.4, 127.7 (4d, 10 arom. CH, C(2), C(2’)); 130.6, 
128.1, 125.0 (3s, 2 arom. Cq, C(4), C(4’), C(5), C(5’)); 47.0, 31.0, 26.9 (3t, 6 CH2); 9.3 
(q, 2 Me). ESI-MS: 431 (17, [M+1]+). Anal. calc. for C26H30N4O2 · 2 H2O (466.59): C 
66.93, H 7.35, N 12.01; found C 67.31, H 7.48, N 12.04. 
8. Synthesis of N-[2-(5-methyl-3-oxy-4-phenylimidazol-1-yl)alkyl]acetamides 18. 
Step 1: AcOEt (0.88 g, 10 mmol) was added to a fourfold excess of a diamine 15 in 
MeOH (25 ml), and the resulting soln. was allowed to stand at r.t. for 4 d. Then, solvent, 
by-product EtOH, excess AcOEt and diamine were removed i.v. to give the 
corresponding N-acetylalkyldiamine 17 as a colorless oily product. 
Step 2: To a soln. of 17 in MeOH (5 ml), paraformaldehyde (0.156 g, 5.2 mmol) was 
added at r.t. and the mixture was stirred for 24 h. Then, the soln. was filtered and the 
solvent removed i.v. to give the corresponding imine as a yellow oil in almost 
quantitative yield. The crude products were used in the next step without purification. 
Step 3: A soln. of the corresponding monoxime dione 10 (1 mmol) and 1.2 mmol of the 
diamine derivative obtained in Step 2 in EtOH (10 ml) was refluxed for 3 h. After 
evaporation of the solvent, the resulting oil was treated with acetone, warmed and 
cooled again. The white precipitate of 18 was collected and recrystallized from an 
appropriate solvent. 
N-[2-(5-Methyl-3-oxy-4-phenylimidazol-1-yl)ethyl]acetamide (18a). Yield: 161 
mg (58%). Colorless solid. M.p. 174–175° (acetone). IR: 3500–2850vs (br.), 1647vs 
(C=O), 1560m, 1444m, 1397m, 1382m, 1348m, 1308m, 1284m, 1258m, 1213m, 769m, 
700m, 601m. 1H-NMR (CDCl3): 8.66 (br. t, NH); 8.35 (s, H–C(2’)); 7.56–7.29 (m, 5 
arom. H); 3.89 (t, CH2); 3.31–3.24 (m, CH2); 2.19, 1.75 (2s, 2 Me). 13C-NMR (CDCl3): 
171.7 (s, C=O); 129.7, 128.6, 128.4, 125.9 (4d, 5 arom. CH, H–C(2’)); 129.3, 127.2, 
123.2 (3s, arom. Cq, C(4’), C(5’)); 44.9, 39.0 (2t, 2 CH2); 22.5, 9.3 (2q, 2 Me). CI-MS: 
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260 (56, [M+1]+), 244 (100), 232 (9), 230 (10), 159 (6). Anal. calc. for C14H17N3O2 · 
H2O (277.33): C 60.63, H 6.91, N 15.15, found: C 60.54, H 6.39, N 15.06. 
N-[3-(4,5-Dimethyl-3-oxyimidazol-1-yl)propyl]acetamide (18b). Yield: 165 mg 
(78%). Colorless needles. M.p. 170–171° (CH2Cl2/petroleum ether). IR: 3350–2850vs 
(br.), 1667vs (C=O), 1559m, 1446m, 1400m, 1383m, 1371m, 1338m, 1293m, 609m. 1H-
NMR (CDCl3): 8.23 (s, H–C(2)); 3.98, 3.20 (2t, 2 CH2); 2.20, 2.14, 1.94 (3s, 3 Me); 
1.93 (m, CH2). 13C-NMR (CDCl3): 173.4 (s, C=O); 127.0, 123.6 (2s, C(4’), C(5’)); 
126.9 (d, C(2’)); 44.5, 37.3, 31.1 (3t, 3 CH2); 22.6, 8.3, 7.1 (3q, 3 Me). EI-MS: 211 (38, 
M+.), 110 (80), 100 (100), 97 (28), 72 (27). Anal. calc. for C10H17N3O2 · 0.25 H2O 
(215.77): C 55.67, H 8.18, N 19.47, found: C 55.76, H 8.27, N 18.59. 
9. Synthesis of 1,1’-(Ethane-1,2-diyl)bis(2,3-dihydro-4,5-dimethylimidazol-2-
one) (19). To a soln. of 16a (286 mg, 1 mmol) in  CHCl3 (10 ml),  a soln. of Ac2O (2 
ml) diluted CHCl3 (2 ml) was added, and the mixture was heated to refluxed for 3 h. 
After cooling, MeOH (5 ml) was added carefully, and stirring was continued for 30 min. 
Then, the solvent was removed, H2O (5 ml) was added, and the colorless 19, containing 
small amounts of N-acetylated derivatives, was filtered and purified by crystallization 
from aq. MeOH. Yield of 19: 140 mg (43%). Colorless solid. M.p. 218–223º 
(MeOH/H2O). IR: 3450–2750vs (br.), 1671vs (C=O), 1460m, 1407s, 1373m, 1315w, 
1114w, 747m, 627m, 558m. 1H-NMR (CDCl3): 3.78 (s, 2 CH2); 1.92, 1.75 (2 br. s, 4 
Me). 13C-NMR (CDCl3): 155.2 (s, C=O); 115.9, 113.7 (2s, C(4), C(4’), C(5), C(5’)); 
41.1 (t, 2 CH2); 9.0, 7.7 (2q, 4 Me). CI-MS: 251 (100, [M+1]+), 138 (11). Anal. calc. for 
C12H18N4O2 · 4 H2O (322.38): C 44.71, H 8.13, N 17.38; found: C 44.69, H 7.94, N 
17.04. 
10. General Procedure for the Synthesis of N,N’-Diacetyl-bis(imidazolones) 20: 
A soln. of an N-oxide 16 (1 mmol) in freshly distilled Ac2O (2 ml) was heated to reflux 
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for 2 h. The mixture was cooled and excess MeOH (10 ml) was added. After 
evaporation of the solvents i.v., H2O (10 ml) was added, and the crude product was 
filtered and recrystallized. 
1,1’-(Ethane-1,2-diyl)bis(3-acetyl-2,3-dihydro-4,5-dimethylimidazol-2-one) 
(20a). Yield: 140 mg (42%). Colorless solid. M.p. (dec.) 232–238° (MeCN). IR: 1717vs 
(C=O(Ac)), 1675s (C=O), 1449m, 1403s, 1386s, 1370s, 1316s, 1178m, 1106m, 750m, 
579m, 560m. 1H-NMR (CDCl3): 3.78 (s, 2 CH2); 2.63 (s, 2 MeCO); 2.34, 1.92 (2 br. s, 4 
Me). 13C-NMR (CDCl3): 170.7 (s, 2 MeC=O)); 152.5 (s, 2 C=O); 117.4, 114.0 (2s, 
C(4), C(4’), C(5), C(5’)); 39.4 (t, 2 CH2); 26.0 (q, 2 MeCO); 11.8, 7.8 (2q, 4 Me). CI-
MS: 336 (26), 335 (100, [M+1]+), 293 (7). Anal. calc. for C16H22N4O4 (334.38): C 
57.47, H 6.63, N 16.76; found: C 57.21, H 6.86, N 16.36. 
1,1’-(Butane-1,4-diyl)bis(3-acetyl-2,3-dihydro-4,5-dimethylimidazol-2-one) 
(20b). Yield: 76 mg (21%). Colorless solid. M.p. 188–189° (MeOH/H2O). IR: 1709vs 
(C=O(Ac)), 1673s (C=O), 1457m, 1438m, 1386s, 1370s, 1317s, 1173w, 1106w, 967w, 
749w, 678m, 599m. 1H-NMR (CDCl3): 3.60 (t, 2 CH2); 2.63 (s, 2 MeCO); 2.24, 1.97 (2 
br. s, 4 Me); 1.68–1.65 (m, 2 CH2). 13C-NMR (CDCl3): 170.9 (s, 2 MeC=O)); 152.5 (s, 
2 C=O); 117.4, 113.8 (2s, C(4), C(4’), C(5), C(5’)); 40.5, 26.7 (2t, 4 CH2); 26.1 (q, 2 
MeCO); 11.8, 8.2 (2q, 4 Me). CI-MS: 364 (23), 363 (100, [M+1]+), 321 (10). Anal. calc. 
for C18H26N4O4 (362.43): C 59.65, H 7.23, N 15.46; found: C 59.29, H 7.17, N 15.28. 
1,1’-(Hexane-1,6-diyl)bis(3-acetyl-2,3-dihydro-4,5-dimethylimidazol-2-one) 
(20c). Yield: 101 mg (25%). Colorless solid. M.p. (dec.) 167–170° (MeOH). IR: 1710vs 
(C=O(Ac)), 1674m (C=O), 1448w, 1407m, 1390m, 1368s, 1312s, 1166w, 1106w, 
1051w, 969w, 908w, 751m, 676w, 607w, 590m. 1H-NMR (CDCl3): 3.54 (t, 2 CH2); 2.63 
(s, 2 MeCO); 2.24, 1.96 (2 br. s, 4 Me); 1.63–1.59, 1.40–1.35 (2m, 4 CH2). 13C-NMR 
(CDCl3): 171.0 (s, 2 MeC=O); 152.4 (s, 2 C=O); 117.5, 113.6 (2s, C(4), C(4’), C(5), 
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C(5’)); 40.5, 26.7, 26.4 (3t, 6 CH2); 26.1 (q, 2 MeCO); 11.8, 8.2 (2q, 4 Me). CI-MS: 392 
(25), 391 (100, [M+1]+), 349 (6), 306 (4). Anal. calc. for C20H30N4O4 · 0.5 H2O 
(399.50): C 60.13, H 7.82, N 14.02; found: C 60.46, H 7.17, N 13.88. 
11. Synthesis of 1,1’-(Butane-1,4-diyl)bis(3-acetyl-2,3-dihydro-4,5-
dimethylimidazol-2-thione)  (21). To a soln. of 16e (332 mg trihydrate, 1 mmol), a soln. 
of 2,2,4,4-tetramethylcyclobutane-1,3-dithione (95 mg, 0.55 mmol) in CHCl3 (2 ml) 
was added drop-wise, and the mixture was stirred overnight at r.t. The precipitate was 
filtered, washed with cold EtOH and Et2O, and the obtained solid was analyzed without 
further purification. Yield of 21: 196 mg (63%). Colorless solid. M.p. (dec.) 271–277o. 
IR: 3450–2700vs (br.), 1659m, 1495s, 1441m, 1406m, 1369m, 1319m, 1250m, 1166m, 
780m, 684m. 1H-NMR ((D6)DMSO): 11.81 (br. s, 2 NH); 3.90 (t, 2 CH2); 2.04, 1.95 (2s, 
4 Me); 1.68–1.51 (m, 2 CH2). 13C-NMR ((D6)DMSO): 158.8 (s, C=S); 120.5, 118.7 (2s, 
C(4), C(4’), C(5), C(5’)); 43.0, 25.5 (2t, 4 CH2); 8.6, 8.4 (2q, 4 Me). EI-MS: 310 (100, 
M+.), 183 (84), 149 (54), 128 (32). Anal. calc. for C14H22N4S2 (310.49): C 54.16, H 7.14, 
N 18.04; found C 53.92, H 6.91, N 17.82. 
12. Synthesis of 1,1’-(Butane-1,4-diyl)bis(3-acetyl-2,3-dihydro-4,5-
dimethylimidazole)  (22) by deoxygenation of 16f. To a soln. of 16f (378 mg 
tetrahydrate, 1 mmol) in EtOH (2 ml), a suspension of freshly prepared Raney-Nickel in 
EtOH was added in small portions. The progress of the reaction was monitored by 
means of TLC (MeOH/AcOEt 1:3). When the 16f was completely reduced, the mixture 
was filtered and the filtrate was concentrated i.v. The crude product was purified by 
crystallization from EtOH to give 22. Yield: 302 mg (76%). Colorless crystals. M.p. 
163–164º. IR: 3120–2850vs (br.), 1602s, 1510s, 1495m, 1445m, 1371m, 1277m, 1261s, 
944m, 850m, 769s, 696vs, 636m. 1H-NMR (CDCl3): 7.67–7.21 (m, 10 arom. H); 7.48 (s, 
H–C(2), H–C(2’)); 3.87 (t, 2 CH2); 2.38 (s, 2 Me); 1.81–1.73, 1.43–1.35 (2m, 4 CH2). 
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13C-NMR (CDCl3): 138.1, 135.3, 123.0 (3s, 2 arom. Cq, C(4), C(4’), C(5), C(5’)); 135.9, 
128.4, 127.0, 126.2 (4d, 10 arom. CH, C(2), C(2’)); 44.9, 30.6, 26.3 (3t, 6 CH2); 9.9 (q, 
2 Me). ESI-MS: 399 (100, [M+1]+). Anal. calc. for C26H30N4 (398.56): C 78.36, H 7.59, 
N 14.06; found: C 77.92, H 6.90, N 13.79. 
13. X-Ray Crystal-Structure Determination of 11a and 16b (Table and Figs. 1-
2)4). All measurements were performed on a Nonius KappaCCD diffractometer [27] 
using graphite-monochromated MoKα radiation (λ 0.71073 Å) and an Oxford 
Cryosystems Cryostream 700 cooler. The data collection and refinement parameters are 
given in the Table, and views of the molecules are shown in Figs. 1 and 2. Data 
reduction was performed with HKL Denzo and Scalepack [28]. The intensities were 
corrected for Lorentz and polarization effects but not for absorption. Equivalent 
reflections were merged. The structures were solved by direct methods using SIR92 
[29], which revealed the positions of all non-H-atoms. The asymmetric unit of 11a 
contains one zwitterionic molecule and half of a H2O molecule, which sits on a C2-axis, 
while that of 16b contains one half of the heterocyclic molecule, which sits across a C2-
axis, plus one H2O molecule in a general position. The non-H-atoms of 11a and 16b 
were refined anisotropically. The H-atoms of the OH group and the H2O molecule of 
11a and the H-atoms of the H2O molecule of 16b were placed in the positions indicated 
by a difference electron density map and their positions were allowed to refine with 
individual isotropic displacement parameters. All remaining H-atoms were placed in 
geometrically calculated positions and refined using a riding model where each H-atom 
                                                          
4) CCDC-646512–646513 contain the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from the Cambridge Crystallographic 
Data Centre, via www.ccdc.cam.ac.uk/data_request/cif. 
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was assigned a fixed isotropic displacement parameter with a value equal to 1.2 Ueq of 
its parent C-atom (1.5 Ueq for the Me groups). The refinement of each structure was 
carried out on F2 using full-matrix least-squares procedures, which minimized the 
function Σw(Fo2 – Fc2)2. In the case of 11a, a correction for secondary extinction was 
applied, and one reflection, whose intensities was considered to be an extreme outlier, 
was omitted from the final refinement. Neutral atom scattering factors for non-H-atoms 
were taken from [30a], and the scattering factors for H-atoms were taken from [31]. 
Anomalous dispersion effects were included in Fc [32]; the values for f' and f" were 
those of [30b]. The values of the mass attenuation coefficients are those of [30c]. All 
calculations were performed using the SHELXL97 [33] program. 
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Legends 
 
Table 1. Imidazole N-Oxides 11 Prepared from 10 and 12 
 
Table 2. Prepared Bis-imidazole N-Oxides 16 
 
Table 3.  Crystallographic Data for Compounds 11a and 16b 
 
 
Fig. 1. ORTEP-Plot [24] of the molecular structure of 11a (arbitrary numbering of the 
atoms, 50% probability ellipsoids, the H2O molecule is not shown) 
 
Fig. 2. ORTEP-Plot [24] of the molecular structure of 16b (arbitrary numbering of the 
atoms, 50% probability ellipsoids, the H2O molecule is not shown) 
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Table 1. Imidazole 3-Oxides 11 Prepared from 10 and 12 
 
11 R1 R2 R3 Yield [%] M.p. [º] 
a HO−CH2–CH2– Me Me 88 106–107 
b HO−CH2–CH2– Ph Me 81 186–188 
c HO−CH2–CH2– Ph Ph 89 197–198 
d HO−CH2–CH2– Me Ph 55 165–167 
e HO−CH2–CH2–CH2– Ph Me 94 140–142 
f HO−CH2–CH2–CH2– Ph Ph 47 191–193 
g HO−CH2–CH2–CH2– Me Ph 66 139–140 
h Me–CH(OH)–CH2– Ph Me 90 143–145 
i Me–CH(OH)–CH2– Ph Ph 92 182–184 
j (S)-Me–CH(OH)–CH2– Me Me 82 119–120 
k HO−CH2–CH(Et)– Ph Me 86 171–174 
l HO−CH2–CH(Et)– Ph Ph 71 199–200 
m 
(S,S)-PhCH(OH)–
CH(CH2OH)– 
Ph Me 52 177–178 
 
 
Table 2. Prepared Bis(imidazole 3-oxides) 16 
 
16 n R1 R2 Yield [%] M.p. [°] 
a 1 H Me 48 231–236 
b 1 H Ph 42 236–240 
c 1 Me Ph 35 234–237 
d 2 H Me 11 191–196 
e 3 H Me 47 151–155 
f 5 H Me 43 101–104 
g 5 H Ph 53 188–192 
 
  
 32 
Table 3.  Crystallographic Data for Compounds 11a and 16b 
__________________________________________________________________________________ 
 
 11a 16b 
__________________________________________________________________________________ 
 
Crystallized from CHCl3/hexane EtOH 
Empirical formula C7H12N2.0.5H2O C22H22N4O2.2H2O 
Formula weight 165.19 410.47 
Crystal color, habit colorless, prism colorless, plate 
Crystal dimensions [mm] 0.25 × 0.25 × 0.25 0.05 × 0.17 × 0.22 
Temperature [K] 160(1) 160(1) 
Crystal system monoclinic orthorhombic 
Space group C2/c Aba2 
Z 8 4 
Reflections for cell determination 2566 1341 
2θ range for cell determination [°] 4–60 4–55 
Unit cell parameters a [Å] 11.1258(2) 24.0599(8) 
 b [Å] 11.8321(3) 10.8504(3) 
 c [Å] 12.9472(3) 7.7711(3) 
 β [°] 99.040(2) 90  
 V [Å3] 1683.22(7) 2028.7(1) 
Dx [g cm
–3
] 1.304 1.344 
µ(MoKα) [mm
–1
] 0.0993  0.0941 
Scan type φ and ω  φ and ω 
2θ(max) [°] 60 55 
Total reflections measured 21719 13330 
Symmetry independent reflections 2460 1248 
Reflections with I > 2σ(I) 2006 1127 
Reflections used in refinement 2459 1248 
Parameters refined; restraints 116; 0 145; 1 
Final R(F)  [I > 2σ (I) reflections] 0.0423  0.0374 
 wR(F
2
)  (all data) 0.1154  0.0945 
Weighting parameters [a; b]a) 0.0542; 0.7192 0.0445; 1.0001 
Goodness of fit 1.057 1.122 
Secondary extinction coefficient 0.009(2) - 
Final ∆max/σ 0.001 0.001 
∆ρ (max; min) [e Å
–3
] 0.21; –0.25 0.16; –0.20 
 
a) w–1 = σ 2(Fo2) + (aP)2 + bP  where P = (Fo2 + 2Fc2)/3 
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